Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hyphens Pharma InternationalSGX:1J5 -2.70%82 ROA % is 7.10% as of Jun. 2026, which is 11% below its 10-year median of 8.00. GuruFocus rates SGX:1J5 with a GF Score™ of 82/100 and a GF Value™ of S$0.31 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 122 Medical Distribution companies, Hyphens Pharma International ranks better than 85.25% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Hyphens Pharma International's annualizedNet Income for the quarter that ended in Jun. 2026 was S$8.7 Mil.
Hyphens Pharma International's average Total Assets over the quarter that ended in Jun. 2026 was S$122.6 Mil. Therefore, Hyphens Pharma International's annualized ROA % for the quarter that ended in Jun. 2026 was 7.10%.
The historical rank and industry rank for Hyphens Pharma International's ROA % or its related term are showing as below:
SGX:1J5'
s ROA % Range Over the Past 10 Years
Min: 4.51 Med: 8 Max: 11.74
Current: 6.97
During the past 11 years, Hyphens Pharma International's highest ROA % was 11.74%. The lowest was 4.51%. And the median was 8.00%.
SGX:1J5's ROA % is ranked better than 85.25% of 122
companies
in the Medical Distribution industry
Industry Median: 2.405
vs SGX:1J5: 6.97
Hyphens Pharma International (SGX:1J5) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Jun. 2026) net income data. The Revenue data used here is two times the semi-annual (Jun. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Hyphens Pharma International ROA % Related Terms
Hyphens Pharma International ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Hyphens Pharma International's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyphens Pharma International ROA % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Hyphens Pharma International's ROA % distribution charts can be found below:
* The bar in red indicates where Hyphens Pharma International's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Jun. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Hyphens Pharma International (SGX:1J5) has a ROA % of 7.10% as of Jun. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Hyphens Pharma International and its competitors. This is 11% below median its historical median of 8.00. Over the past decade, Hyphens Pharma International's ROA % has ranged from 4.51 to 11.74. According to the industry distribution chart, Hyphens Pharma International ranks #18 out of 122 companies in the Medical Distribution industry, placing it in the top 14.8%.
Is Hyphens Pharma International's ROA % too high?
Hyphens Pharma International's current ROA % of 7.10% is 11% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 4.51 to a high of 11.74. The Medical Distribution industry median ROA % is 2.41. Hyphens Pharma International's value of 7.10% is 195.2% above this industry median. Based on the distribution chart, Hyphens Pharma International ranks #18 out of 122 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Hyphens Pharma International has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hyphens Pharma International's ROA % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Hyphens Pharma International ranks #18 out of 122 companies for ROA %. This places Hyphens Pharma International in the top 15% of its industry — outperforming the majority of peers. The industry median ROA % is 2.41. Hyphens Pharma International's value of 7.10% is 195.2% above this benchmark. Historically, Hyphens Pharma International's own ROA % has ranged from 4.51 to 11.74 over the past decade. While the company's 10-year median is 8.00 vs. the industry median of 2.41, Hyphens Pharma International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Distribution company?
The median ROA % among Medical Distribution companies is 2.41, based on 122 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyphens Pharma International's current ROA % of 7.10% is 195.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Hyphens Pharma International and its competitors. For the Medical Distribution industry, the median ROA % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyphens Pharma International's current ROA % is 7.10%, which is 11% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyphens Pharma International stock overvalued right now?
Based on GuruFocus' analysis, Hyphens Pharma International (SGX:1J5) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.31, compared to a current price of S$0.36 — trading 16.1% above its estimated fair value. The current ROA % is 7.10%, which is 11% below median its 10-year median of 8.00 and 195.2% above the Medical Distribution industry median of 2.41. Hyphens Pharma International's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Hyphens Pharma International (SGX:1J5), the current ROA % is 7.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyphens Pharma International (SGX:1J5) Overvalued in 2026?
Based on GuruFocus' analysis, Hyphens Pharma International stock appears to be overvalued.
The current stock price of S$0.36 is trading 16.1% above its estimated GF Value™ of S$0.31.
GuruFocus considers Hyphens Pharma International to be Modestly Overvalued.
Key valuation signals for SGX:1J5:
ROA %: 7.10% (11% below median its 10-year median of 8.00)
GF Value™: S$0.31 vs. price of S$0.36 (16.1% above fair value)
Industry Position: 195.2% above the Medical Distribution median (#18 of 122)
No single metric tells the full story. See the SGX:1J5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyphens Pharma International Ltd is a pharmaceutical company. Its segments include the Pharmaceutical and Medical Aesthetics segment; Proprietary Brands segment; and Digital Platform and E-Pharmacy segment. The Pharmaceutical and Medical Aesthetics segment engages in the business of marketing and selling a range of pharmaceutical and medical aesthetics products with exclusivity in the relevant ASEAN countries. The Proprietary Brands segment develops, markets, and sells dermatological, pharmaceuticals and health supplement products. The Digital Platform and E-Pharmacy segment is a digital platform servicing procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies, mainly in Singapore.
82GF Score
Get the complete analysis for SGX:1J5
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:1J5 has been successfully added to your 
